Medivation
Amgen looking to join the fray, mulling Medivation bid – Reports
May 5, 2016Research and Development, Sales and Marketing Amgen, AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
Biotech firm Amgen (Nasdaq: AMGN) is mulling a bid for Medivation (Nasdaq: MDVN), the latest to join the growing list …
Sanofi sends letter to Medivation board; claims shareholders want takeover
May 5, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Medivation, Sanofi, board, brandicourt, hostile, shareholders, takeover
The CEO of Sanofi has issued a strongly worded letter to the board at Medivation, indicating that shareholders support their …
Pfizer joins the race, bids for Medivation – Reports
May 4, 2016Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Deals, M&A, MA, Medivation, Pfizer, Sanofi
US pharma giant Pfizer (NYSE: PFE) is rumoured to have joined the list of suitors vying for the Medivation (Nasdaq: …
Board at Medivation unanimously reject Sanofi bid
April 29, 2016Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover
The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …
Sanofi makes unsolicited $9.8 billion bid for Medivation
April 28, 2016Research and Development, Sales and Marketing M&A, MA, Medivation, Sanofi, deal, unsolicited offer
French drugmaker Sanofi (Euronext: SAN) on Thursday said it has made an offer to buy Medivation (Nasdaq: MDVN) for about $9.8 …
AstraZeneca hold internal talks for Medivation takeover – reports
April 18, 2016Manufacturing and Production, Sales and Marketing 7 billion, AstraZeneca, Medivation, Sanofi, jp morgan, merger, takeover
AstraZeneca (LSE: AZN) is said to have held initial internal talks concerning a potential £7 billion offer for US drug …
US lawmakers demand price cut for Astellas, Medivation’s prostate cancer drug Xtandi
March 30, 2016Business Services, Manufacturing and Production, Research and Development, Sales and Marketing Astellas, Japan, Medivation, US FDA, Xtandi, drug price
US lawmakers have asked the National Institutes of Health and the Department of Health and Human Services to ‘use its …
Phase III trial initiated for enzalutamide in treatment of prostate cancer
March 24, 2016Research and Development Astellas, Medivation, arches, clinical trial, enzalutamide, phase 3, phase III, prostate cancer
Astellas Pharma (TSE: 4503) and Medivation (NASDAQ:MDVN) have announced the initiation of the ARCHES Phase III clinical trial to evaluate …
FDA approves new indication for Xtandi
September 11, 2014Sales and Marketing Astellas, FDA, Medivation, Xtandi, Zytiga, prostate
The FDA has approved Astellas Pharma and Medivation’s prostate cancer drug Xtandi (enzalutamide) for use in patients who have not …
Astellas submits new prostate cancer drug to EMA
June 28, 2012Research and Development, Sales and Marketing Astellas, EMA, Medivation, NICE, Zytiga, enzalutamide
Astellas has submitted its investigational prostate cancer drug enzalutamide to the European Medicines Agency. Enzalutamide is a once-daily pill that works …
Prostate cancer drug extends life after chemotherapy
March 29, 2012Research and Development, Sales and Marketing Astellas, Medivation, Zytiga, prostate cancer
Prostate cancer treatment MDV3100 has been shown to extend life by nearly five months in men with advanced disease who …
Pfizer pulls plug on Alzheimer’s drug
January 18, 2012Research and Development, Sales and Marketing Medivation, Pfizer, dimebon
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …
Pfizer suffers Alzheimer’s setback
March 4, 2010Research and Development Alzheimer's, Medivation, Pfizer
Pfizer has suffered a big setback with the oral Alzheimer’s disease treatment it is developing with biotech outfit Medivation. Investigational …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
